Opko Health Inc (OPK)

[tomsylver]

OPKO Announces Presentation of Data on Long-Acting Oxyntomodulin at Diabetes Conference


MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc.(NYSE: OPK) today announced that it will present data on its long acting oxyntomodulin (MOD-6030) product on April 25, 2014at the 7th Diabetes Drug Discovery and Development Conference being held in Cambridge, MA. Company scientists will make an oral presentation discussing MOD-6030, the company's long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity. Pre-clinical data shows the drug induced a marked weight loss and food intake inhibition in both animal models which were superior compared to those with bi-daily injections of native OXM and to bi-daily injections of existing marketed drugs.

The 7th Diabetes Drug Discovery and Development Conference is being held April 23-25, in Cambridge, MA. For more information, visit: http://www.gtcbio.com/conference/diabetes-drug-discovery-and-development-overview.